Hiring with precision: how biotech investment headwinds impact leadership hiring

After several record years for biotech investment, the market has taken a downward turn in the past year.

Precision BioSearch secures CEO for Oxford spin-out, Dark Blue Therapeutics

Precision BioSearch partnered with Dark Blue Therapeutics, a biotech company developing a pipeline of oncology programs from the University of Oxford and therapeutics accelerator LAB282.

Pangea appoints Alleyn Plowright as VP, Drug Discovery & Preclinical Development

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

2022 – A Year in Review Highlights & successes in supporting the biotech sector

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

Our Co-founder, Jemma Challinor, presents at the OBN Awards 2022

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

Malcolm Silander is speaking at ‘Building Success for your Organisation’.

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

Precision BioSearch is delighted to be sponsoring the OBN Awards 2022

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

Precision BioSearch secures CSO for leading cell and gene therapy company, Ixaka

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

Tom Coulter joins Dalriada as Head, Drug Discovery Programs and Partnerships

Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.

New Oxford spin-out, Alethiomics, appoints Dr Edward Ainscow as CSO

Precision BioSearch is pleased to have partnered with Oxford Science Enterprises during the launch phase of Alethiomics to secure Dr Edward Ainscow as CSO